---
title: "keynote-048"
date: "2024-09-28"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[palliative_intent-of-hnscc]]

# keynote-048

In patients with recurrent or metastatic head and neck squamous cell carcinoma, pembrolizumab alone or in combination with chemotherapy significantly improved overall survival compared to cetuximab plus chemotherapy, with higher adverse events in the combination groups, while neither pembrolizumab regimen demonstrated improvement in progression-free survival.

![h:450px](https://i.imgur.com/STCTam7.png)

> 1.Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7
> Ho AL. Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology. Published online February 1, 2023.
